The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories
Honoraria - CStone Pharmaceuticals
Consulting or Advisory Role - Bayer; Blueprint Medicines; Daiichi; deciphera; Immunicum; Kayothera; Lilly; MORE Health; Research to Practice; UpToDate
Research Funding - Blueprint Medicines (Inst); Daiichi Sankyo RD Novare (Inst); Deciphera (Inst); Eisai (Inst); Merck (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Expert Testimony - Bayer
Other Relationship - Research to Practice; WCG
 
Michael C. Heinrich
Honoraria - Novartis
Consulting or Advisory Role - Blueprint Medicines; Deciphera; Novartis; Theseus Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent on treatment of GIST-licensed to Novartis (Inst)
 
Neeta Somaiah
Stock and Other Ownership Interests - JNJ (I); Pfizer (I)
Consulting or Advisory Role - AADi; Bayer; Blueprint Medicines; Boehringer Ingelheim; Deciphera; Epizyme
Research Funding - Ascentage Pharma; AstraZeneca/MedImmune (Inst); Daiichi Sankyo/Lilly; Deciphera; GlaxoSmithKline; Karyopharm Therapeutics
 
Brian Andrew Van Tine
Leadership - Polaris
Honoraria - Bionest Partner; Horizon CME; Research to Practice; Targeted Oncology
Consulting or Advisory Role - Adaptimmune; ADRx; Apexigen; Ayala Pharmaceuticals; Bayer; Cytokinetics; Daiihi Sankyo; Deciphera; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Intellisphere; Lilly; Novartis; Pfizer
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline; Lilly
 
Robert McLeod
Employment - Daiichi Sankyo
Research Funding - Daiichi Sankyo
 
Abderrahmane Laadem
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Ben Cheng
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Satoshi Nishioka
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Madan Gopal Kundu
Employment - Abbvie; Daiichi Sankyo Inc.
Stock and Other Ownership Interests - Daiichi Sankyo Inc.
 
Xiaozhong Qian
Employment - Bristol-Myers Squibb (I); Daiichi Sankyo
Stock and Other Ownership Interests - Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Pfizer/Astellas
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb; Daiichi Sankyo, Inc.
 
Yvonne Y. Lau
Employment - Daiichi Sankyo
 
Brittany Tran
No Relationships to Disclose
 
Prasanna Kumar
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Ololade Dosunmu
Employment - Sarah Cannon Research Institute
 
Julia Shi
Employment - Sarah Cannon Research Institute
Research Funding - Sarah Cannon Research Institute
 
Yoichi Naito
Consulting or Advisory Role - AstraZeneca; Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - AstraZeneca; Bayer Yakuhin; Chugai Pharma; FUJIFILM Toyama Chemistry; Gardant Pharmaceuticals; Lilly; Mundipharma; Novartis; Ono Yakuhin; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie; AstraZeneca Japan; Boehringer Ingelheim; Daiichi Sankyo; Eisai; Lilly; Pfizer; Taiho Pharmaceutical